V260 Registration Study (V260-013)(COMPLETED)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 3

Conditions

Rotavirus

Treatments

Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
Biological: Comparator: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00166517
2005_071
V260-013

Details and patient eligibility

About

Immunogenicity and Safety of V260 in Healthy Infants in Korea

Enrollment

178 patients

Sex

All

Ages

6 to 12 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

* At first study vaccination, age 6 weeks through exactly 12 weeks

Exclusion criteria

* History of congenital abdominal disorders, intussusception, or abdominal surgery * History of known prior rotavirus disease * Ongoing chronic diarrhea or failure to thrive * Clinical evidence of active gastrointestinal illness

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

178 participants in 2 patient groups, including a placebo group

1
Experimental group
Description:
RotaTeq
Treatment:
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
2
Placebo Comparator group
Description:
Placebo
Treatment:
Biological: Comparator: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems